CDCP1 was reported to promote resistance to trazatuzumab in HER2 positive breast cancer 16, 48, nilotinib in chronic myeloid leukaemia 17 and carboplatin resistance in clear cell EOC 11. This evidence concerns the gene CDCP1 and breast cancer.